The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 20, 2002

Filed:

Feb. 13, 1998
Applicant:
Inventors:

Anthony Michael Slater, Macclesfield, GB;

David Charles Blakey, Macclesfield, GB;

David Huw Davies, Macclesfield, GB;

John Frederick Hennam, Macclesfield, GB;

Laurent Francois Andre Hennequin, Reims Cedex, FR;

Peter Robert Marsham, Macclesfield, GB;

Robert Ian Dowell, Macclesfield, GB;

Assignee:

Zeneca Limited, London, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 9/64 ; C12N 1/557 ; C12N 1/562 ; A61K 3/9395 ; A61K 3/848 ;
U.S. Cl.
CPC ...
C12N 9/64 ; C12N 1/557 ; C12N 1/562 ; A61K 3/9395 ; A61K 3/848 ;
Abstract

Antibody Directed Enzyme Prodrug Therapy (ADEPT) systems for use in cancer based on mutated carboxypeptidase B (CPB) enzymes. Enzyme conjugates for ADEPT are substantially non-immunogenic in humans comprising a targeting moiety (for example an antibody) capable of binding with a tumor associated antigen, the targeting moiety being linked to a mutated form of a CPB enzyme capable of converting a prodrug into an antineoplastic drug wherein the prodrug is not significantly convertible into antineoplastic drug in humans by natural unmutated enzyme. A preferred enzyme mutant is human pancreatic CPB comprising a Lys or Arg residue at position 253. Suitable mustard prodrugs are disclosed in the specification.


Find Patent Forward Citations

Loading…